Trichome Pharma has received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to cultivate medicinal cannabis for research purposes.
Trichome Pharma has been building its research and development platform over the last 18 months. The company’s aim in building the facility is to increase access to medicinal cannabis and set a new benchmark in quality and innovation for medicinal-grade starter materials and finished products.
With the approval of a cultivation licence, the company will now begin the development of novel micropropagation and conservation techniques for large-scale plant production.
Discover the essential elements for producing a successful cannabis crop with PharmaSeeds
It will also study a selection of various cannabis cultivars from its bank of genetics, as well as the development of innovative cultivation strategies and protocols to optimise plant quality, performance and potency.
CEO of Trichome Pharma and Managing Director of Trichome Capital, Nicholas Balk, commented: “Receiving AEMPS approval is a significant milestone for the company that marks the culmination of many months of hard work. It’s a really exciting time to be in this industry. I’ve always believed that Spain is the perfect place to build and grow a cannabis business.
“Not only does it possess a world class agricultural sector and optimal climatic conditions for cannabis cultivation, but it also has a rich ecosystem of knowledgeable industry experts and a deeply-rooted culture in cannabis.
“Of course, we’d love to see domestic regulation evolve in the same way other European markets have and trust this will happen in the not too distant future.”
The company, which is a member of the European Industrial Hemp Association (EIHA), has also launched its new website.
[activecampaign form=31]
